The Food and Drug Administration on Monday approved a new treatment for patients with advanced ovarian cancer — an antibody that delivers a targeted dose of chemotherapy directly to cancer cells.
The new drug, called Elahere, was developed by Immunogen, a biotech company based in Waltham, Mass. It’s the first new treatment option for advanced ovarian cancer to reach the U.S. market in more than seven years, and the first approval of a wholly owned medicine in Immunogen’s 41-year history.
The FDA approved Elahere to treat patients with advanced ovarian cancer no longer responsive to platinum-based chemotherapy. Tumors are also required to contain high levels of a protein called folate receptor alpha on their surface.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
